Allarity Therapeutics, Inc. 8-K

What Happened
Allarity Therapeutics, Inc. announced on May 5, 2026 (filed on Form 8-K) that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib is progressing in line with the planned timeline. The company said the campaign is being executed at its contract development and manufacturing organization (CDMO) and is expected to be completed no later than the third quarter of 2026. The company’s press release dated May 5, 2026 is attached as an exhibit to the filing.

Key Details

• Announced: May 5, 2026 (8-K filed May 6, 2026).
• Program: API manufacturing campaign for stenoparib.
• Location/partner: At Allarity’s contract development and manufacturing organization (CDMO).
• Timeline: Completion expected no later than Q3 2026.

Why It Matters
This 8-K provides a concrete operational update on a development-stage asset, confirming the company’s API manufacturing is proceeding as planned with a specific completion window. For investors, the update signals a defined timeline for a key supply milestone in the stenoparib program (manufacturing of active ingredient), which is an important step in progressing clinical or commercial activities that depend on finished drug substance. The filing does not provide financial results or new clinical data.